Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 252-029-5 | CAS number: 34443-12-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Specific investigations: other studies
Administrative data
Link to relevant study record(s)
- Endpoint:
- biochemical or cellular interactions
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: data from iCSS CompTox Dashboard. Data Quality 100%. Data manually curated with highest confidence
- Principles of method if other than guideline:
- Using a high-throughput robotic screening system, TBEC was assessed for its potential to disrupt biological pathways (DNA binding, growth factor, nuclear receptor (non-steroidal and steroidal), cell cycle, cytochrome P450, hydrolase and cell morphology) that may result in toxicity.
- Type of method:
- in vitro
- Specific details on test material used for the study:
- DSSTOX GSID: 44921
- Remarks:
- 0.0006 to 90µM
- Details on study design:
- See enclosed excel file
- Details on results:
- 113 assays were performed. TBEC was inactive in all assays, therefore, there is no evidence that TBEC could interfere with the expression of the screened genes.
- Executive summary:
Using a high-throughput robotic screening system, TBEC was assessed for its potential to disrupt biological pathways (DNA binding, growth factor, nuclear receptor (non-steroidal and steroidal), cell cycle, cytochrome P450, hydrolase and cell morphology) that may result in toxicity. 113 assays were performed. TBEC was inactive in all assays, therefore, there is no evidence that TBEC could interfere with the expression of the screened genes.
- Endpoint:
- biochemical or cellular interactions
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Principles of method if other than guideline:
- The PubChem BioAssay database was searched for chemogenomic, medicinal chemistry and functional genomics biological activities
- Type of method:
- in vivo
- Specific details on test material used for the study:
- PubChem CID: 61931
PubChem SID: 144211602 - Details on results:
- 150 bioassays with 150 bioactivity outcomes were retrieved from the PubChem BioAssay data base. TBEC was reported as inactive in 137 biossays, inconclusive in 12 bioassays and active in 1 cytotoxicity bioassay. Nevertheless, according to the detailed results of this cytotoxicity assay, there was no demonstration of a toxicological activity.
- Executive summary:
The PubChem BioAssay database was searched for chemogenomic, medicinal chemistry and functional genomics biological activities. 150 bioassays with 150 bioactivity outcomes were retrieved. TBEC was reported as inactive in 137 biossays, inconclusive in 12 bioassays and active in 1 cytotoxicity bioassay. Nevertheless, according to the detailed results of this cytotoxicity assay, there was no demonstration of a toxicological activity. Therefore, TBEC is devoied of activity in cell viability assays, and of agonist and/or antagonist activities on the peroxisome proliferator-activated receptor alpha (PPARa), delta (PPARd) and gamma (PPARg), antioxidant response element (ARE), androgen receptor (AR), estrogen receptor alpha (ER-alpha), thyroid receptor (TR) and glucocorticoid receptor (GR), p53, vitamin D receptor, retinoic acid receptor (RAR), farnesoid-X-receptor (FXR), hypoxia (HIF-1), NFkB, RXR, retinoid-related orphan receptor gamma (ROR-gamma) and aryl hydrocarbon receptor (AhR) signaling pathways.
Referenceopen allclose all
113 assays were performed, all results are displayed in the enclosed excel file.
TBEC was inactive in all assay (see attached figure).
The list of all the assays performed is displayed in the enclosed excel file.
Detailed data on the assay reported as positive are displayed below and in the attached figure.
Activity Value [µM] |
Substance SID |
BioAssay AID |
BioAssay Name |
48.9662 |
144211602 |
743209 |
qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen |
Data for SID 144211602 in AID 743209
Phenotype-Replicate_1 |
Cytotoxic |
Potency-Replicate_1 [uM]* |
48.9662 |
Efficacy-Replicate_1 [%] |
80.4056 |
Analysis Comment-Replicate_1 |
|
Activity_Score-Replicate_1 |
41 |
Curve_Description-Replicate_1 |
Partial curve; high efficacy |
Fit_LogAC50-Replicate_1 |
-4.3101 |
Fit_HillSlope-Replicate_1 |
2.9023 |
Fit_R2-Replicate_1 |
0.9315 |
Fit_InfiniteActivity-Replicate_1 [%] |
-79.6205 |
Fit_ZeroActivity-Replicate_1 [%] |
0.7851 |
Fit_CurveClass-Replicate_1 |
-2.1 |
Excluded_Points-Replicate_1 |
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 |
Max_Response-Replicate_1 [%] |
-62.9701 |
Activity at 0.00107 uM-Replicate_1 [%] |
-3.289 |
Activity at 0.00238 uM-Replicate_1 [%] |
-0.5705 |
Activity at 0.00531 uM-Replicate_1 [%] |
1.9899 |
Activity at 0.012 uM-Replicate_1 [%] |
-4.3088 |
Activity at 0.026 uM-Replicate_1 [%] |
9.1788 |
Activity at 0.059 uM-Replicate_1 [%] |
3.3052 |
Activity at 0.132 uM-Replicate_1 [%] |
-6.3236 |
Activity at 0.275 uM-Replicate_1 [%] |
-5.0525 |
Activity at 0.550 uM-Replicate_1 [%] |
3.6889 |
Activity at 1.225 uM-Replicate_1 [%] |
8.459 |
Activity at 2.701 uM-Replicate_1 [%] |
0.678 |
Activity at 5.947 uM-Replicate_1 [%] |
1.6567 |
Activity at 13.22 uM-Replicate_1 [%] |
-4.8617 |
Activity at 29.14 uM-Replicate_1 [%] |
-18.3784 |
Activity at 62.57 uM-Replicate_1 [%] |
-62.9701 |
Compound QC-Replicate_1 |
QC'd by SIGMA |
Phenotype-Replicate_2 |
Inactive |
Max_Response-Replicate_2 [%] |
15.201 |
Activity at 0.00107 uM-Replicate_2 [%] |
26.1066 |
Activity at 0.00238 uM-Replicate_2 [%] |
1.123 |
Activity at 0.00531 uM-Replicate_2 [%] |
-0.4973 |
Activity at 0.012 uM-Replicate_2 [%] |
18.7334 |
Activity at 0.026 uM-Replicate_2 [%] |
12.6056 |
Activity at 0.059 uM-Replicate_2 [%] |
12.5507 |
Activity at 0.132 uM-Replicate_2 [%] |
0.7704 |
Activity at 0.275 uM-Replicate_2 [%] |
2.2138 |
Activity at 0.550 uM-Replicate_2 [%] |
19.2095 |
Activity at 1.225 uM-Replicate_2 [%] |
2.6449 |
Activity at 2.701 uM-Replicate_2 [%] |
8.3207 |
Activity at 5.947 uM-Replicate_2 [%] |
24.1029 |
Activity at 13.22 uM-Replicate_2 [%] |
1.1825 |
Activity at 29.14 uM-Replicate_2 [%] |
10.9219 |
Activity at 62.57 uM-Replicate_2 [%] |
15.201 |
Phenotype-Replicate_3 |
Inactive |
Max_Response-Replicate_3 [%] |
-16.9007 |
Activity at 0.00107 uM-Replicate_3 [%] |
-20.298 |
Activity at 0.00238 uM-Replicate_3 [%] |
-23.115 |
Activity at 0.00531 uM-Replicate_3 [%] |
0 |
Activity at 0.012 uM-Replicate_3 [%] |
-30.2343 |
Activity at 0.026 uM-Replicate_3 [%] |
0 |
Activity at 0.059 uM-Replicate_3 [%] |
-7.8363 |
Activity at 0.132 uM-Replicate_3 [%] |
-4.6272 |
Activity at 0.275 uM-Replicate_3 [%] |
-11.0875 |
Activity at 0.550 uM-Replicate_3 [%] |
-13.2885 |
Activity at 1.225 uM-Replicate_3 [%] |
-9.6367 |
Activity at 2.701 uM-Replicate_3 [%] |
1.2267 |
Activity at 5.947 uM-Replicate_3 [%] |
-20.8329 |
Activity at 13.22 uM-Replicate_3 [%] |
-8.8938 |
Activity at 29.14 uM-Replicate_3 [%] |
-1.869 |
Activity at 62.57 uM-Replicate_3 [%] |
-16.9007 |
Description of key information
Using a high-throughput robotic screening system (US EPA, 2017), TBEC was assessed for its potential to disrupt biological pathways (DNA binding, growth factor, nuclear receptor (non-steroidal and steroidal), cell cycle, cytochrome P450, hydrolase and cell morphology) that may result in toxicity. 113 assays were performed. TBEC was inactive in all assays, therefore, there is no evidence that TBEC could interfere with the expression of the screened genes.
The PubChem BioAssay database was searched for chemogenomic, medicinal chemistry and functional genomics biological activities (NCBI, 2017). 150 bioassays with 150 bioactivity outcomes were retrieved. TBEC was reported as inactive in 137 biossays, inconclusive in 12 bioassays and active in 1 cytotoxicity bioassay. Nevertheless, according to the detailed results of this cytotoxicity assay, there was no demonstration of a toxicological activity. Therefore, TBEC is devoied of activity in cell viability assays, and of agonist and/or antagonist activities on the peroxisome proliferator-activated receptor alpha (PPARa), delta (PPARd) and gamma (PPARg), antioxidant response element (ARE), androgen receptor (AR), estrogen receptor alpha (ER-alpha), thyroid receptor (TR) and glucocorticoid receptor (GR), p53, vitamin D receptor, retinoic acid receptor (RAR), farnesoid-X-receptor (FXR), hypoxia (HIF-1), NFkB, RXR, retinoid-related orphan receptor gamma (ROR-gamma) and aryl hydrocarbon receptor (AhR) signaling pathways.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.